Antibodies Contract Manufacturing Market 2022
The Antibodies Contract Manufacturing Market ought to witness an explicit In Upcoming Years. With geographical barriers out of sight, track-and-trace programs are on the verge to reach their zenith in the timespan mentioned above. This could be credited to OEMs trying to reach out to the end-users remotely through virtual setups. Plus, people are getting a broader choice regarding choosing the experts. This holds for preventive as well as curative measures. The trend is certain to embark upon massive transience in the years to come.
The global antibodies contract manufacturing market is worth US$ 4.3 Bn at present, and is set to expand 3.4X over the next ten years. The market is expected to reach US$ 14.6 Bn by 2031, expanding at a CAGR of 13%.
Get Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/32933
As per Persistence Market Research’s latest industry analysis, the global antibodies contract manufacturing market was valued at 3.87 Bn in 2020, and is expected to exhibit a high CAGR of close to 13% over the forecast period (2021-2031).
Rising prevalence cancer and infectious diseases is creating rapid development and commercialization need for biopharmaceutical therapeutics. Ultimately, rise in the prevalence of both conditions is expected to drive the need for biologics.
With advancements in contract solutions, leading CDMOs are focusing on the expansion of their integrated capabilities from molecule-to-finished product. The trend is significant as the acceleration of development and speed to market is becoming more crucial for biopharmaceutical and biologics developers.
Owing to their high specificity and favorable safety profile associated with antibodies, contract manufacturing outsourcing presently comprises the largest class of biologics in the business, owing to legacy challenges related to the development and manufacturing of biologics.
- For example, in July 2020, Avid Bioservices and Argonaut Manufacturing Services entered into agreement to offer biotechnology and pharmaceutical clients integrated process development, drug substance manufacturing, and drug product parenteral manufacturing, to accelerate the development and commercialization of biopharmaceutical therapeutics.
Focusing on reduction in operating costs through outsourcing of R&D and commercialization of antibodies to CMOs/CDMOs could increase operational efficiency. Outsourcing at later stages of clinical development through identification and appointment of a strategic partner could improve efficiencies all along the value chain.
The current biologics-development pipeline supports an outlook of continued healthy growth. The number of biotech patents applied for every year has been growing at approximately 23% annually. According to Persistence Market Research, there are currently more than 1,500 biomolecules undergoing clinical trials, which targeting more than 100 hundred types of diseases, and the success rate for biologics has so far been over twice that of small-molecule products.
Request For Customization@https://www.persistencemarketresearch.com/request-customization/32933
Key Takeaways from Market Study
- In terms of product, monoclonal antibodies hold around 89% market value share.
- Based on expression system, the mammalian segment is leading with over 84.1% market.
- Based on company size, mid-sized companies account the largest market share of 45.9%.
- By scale of operation, commercial operations account for 54.3% market share.
- By region, North America is set dominate the global antibodies contract manufacturing market with a value share of around 37.9% in 2021. Europe is slated to be the second-largest market with a value share of around 29.7% in 2021.
“Strong biologics pipeline and growing contract manufacturing service adoption are expected to drive market growth over the coming years,” says an analyst of Persistence Market Research.
Market Competition
New product launches and approvals, agreements, expansion, acquisition collaborations, and partnerships have emerged as key growth strategies being adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.
- In February 2021, Avid Bioservices, Inc. began phase 2 expansion of its Myford manufacturing capacity expansion plan. This expansion will help the company cater the growing demand for contract manufacturing services
- Rentschler Biopharma, in May 2020, entered into a collaboration with Genemab for the development and manufacturing of bispecific antibodies generated with Genmab’s DuoBody Technological Platform.
- In August 2018, KBI Biopharma’s subsidiary KBI Biopharma BVBA established its new laboratory in Belgium. With this expansion, the company will be able to offer analytical services in the European market.
Buy Now@https://www.persistencemarketresearch.com/checkout/32933
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the antibodies contract manufacturing market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.
About us: –
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Contact Us:
Persistence market research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]